NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
IPO Year:
Exchange: NASDAQ
Website: nanovibronix.com
NanoVibronix, Inc. (NASDAQ:NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on October 14, 2022. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 17, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding sh
S-1/A - NanoVibronix, Inc. (0001326706) (Filer)
S-1/A - NanoVibronix, Inc. (0001326706) (Filer)
8-K - NanoVibronix, Inc. (0001326706) (Filer)
8-K - NanoVibronix, Inc. (0001326706) (Filer)
10-K - NanoVibronix, Inc. (0001326706) (Filer)
8-K - NanoVibronix, Inc. (0001326706) (Filer)
8-K - NanoVibronix, Inc. (0001326706) (Filer)
8-K - NanoVibronix, Inc. (0001326706) (Filer)
S-1 - NanoVibronix, Inc. (0001326706) (Filer)
8-K - NanoVibronix, Inc. (0001326706) (Filer)
NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on
Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Recent Business Highlights Revenue of $272,000, an increase of 164% compared to the prior year period Significant backlog of orders to be filled in Q2 Supply chain challenges are expected to abate moving into the second half of 2022 Submitted a 510(k) application to the U.S. Food and Dr
MONTREAL, April 29, 2022 /CNW Telbec/ - Cerro de Pasco Resources Inc. (CSE:CDPR) (Frankfurt: N8HP) ("CDPR" or the "Company") announces that it has applied to the Autorité des marchés financiers (Québec) (the "AMF"), as principal regulator of the Company, and expects to be granted a management cease trade order (the "MCTO") on May 2, 2022, pursuant to Policy Statement 12-203 Respecting Management Cease Trade Orders ("PS 12-203"). Under the MCTO, the Company's Chief Executive Officer (CEO), Chief Financial Officer (CFO) and directors may not trade in securities of the Company until such time as the Company files its audited consolidated financial statements, its management's discussion and ana
NanoVibronix, Inc., (NASDAQ:NAOV) (the "Company"), a healthcare device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, announced that the Company's Annual Meeting of Stockholders was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2021. All of the resolutions submitted for stockholder approval were adopted, including: Election of the six director nominees Approval of the amendment to the company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock. Ratification of appointment of Marcum LLP as the company's independent re
SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)
SC 13G - NanoVibronix, Inc. (0001326706) (Subject)
SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)
SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)
SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company" or "NanoVibronix"), a medical technology company specializing in non-invasive therapeutic devices, today announced that on April 9, 2025, Nasdaq formally notified the Company that it has evidenced full compliance with all criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price and $2.5 million stockholders' equity requirements. Accordingly, the previously disclosed Nasdaq listing matter has been closed. Pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor until April 9, 2026. About NanoVibronix, Inc. NanoVibronix, Inc. (NASDAQ:NAOV) is a medical device company hea
Publication of Independent Study Heightens Demand for UroShield NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company" or "NanoVibronix"), a medical technology company specializing in non-invasive therapeutic devices, today announced the renewal and expansion of its exclusive three-year distribution agreement with Dukehill Healthcare Pty Ltd. ("Dukehill"). Dukehill, with its Head Office in Queensland, has primarily focused its clinical projects and sales efforts within the state and in New South Wales. However, the recent expansion of the agreement with the Company now extends across all Australian States, with notable growth in South Australia and Victoria. This surge follows an increasing numb
UroShield Cited as Effective in Preventing CAUTIs and Blockages, Having a Major Impact on Quality of Life and Reducing Healthcare Resource Costs NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical technology company specializing in non-invasive therapeutic devices, today announced that an independent health service study of its UroShield® is published in The Australian and New Zealand Continence Journal. The study highlights UroShield's effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and recommends its adoption for appropriate patients with indwelling urinary catheters (IUCs). Researchers found that patients using UroShield experienced an 86% redu
Common Stock Will Begin Trading on Split-Adjusted Basis on March 14, 2025 NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the "common stock") at a ratio of 1 post-split share for every 11 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Thursday, March 13, 2025. The Company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol NAOV and will begin trading on a split-adjusted basis when the market opens on Friday, March
NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical technology company specializing in non-invasive therapeutic devices, today announced the completion of the acquisition of ENvue Medical Holdings Corp. ("ENvue") (the "Acquisition"), a privately-held, innovative leader in enteral feeding solutions. This strategic transaction will combine the strengths of both companies, creating a platform for growth and expanded market reach in the medical device sector. The Company believes that the Acquisition will strengthen the combined company's market position in enteral feeding technology and therapeutic medical devices, as ENvue's proprietary technology aligns with the Company's commitment
Development advancing to verification and testing phase; Aims to future-proof design, lower componentry costs and improve manufacturing NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced a third-party contractor engaged by the Company has completed the design phase for the development of the Company's next generation PainShield® and UroShield® devices. During the design phase, which was completed in December 2024, the third-party contractor developed prototypes of the Company's next generation PainShield® and UroShield® d
Research expected to advance to ‘Full Study' phase in 2025 NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced the successful completion of the first phase of a Randomized Control Trial study of UroShield® by researchers at the University of Michigan ("UM"). This first phase of the trial is a precursor to the full study by researchers at UM. It was conducted primarily with nursing home residents and was aimed at studying the impact of UroShield® on improving patient's quality of life by its potential to reduce urinary trac
Extends Relationship with Ultra Pain Products, Inc for Distribution of PainShield for Five Years NanoVibronix, Inc., (NASDAQ:NAOV) (the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has renewed its exclusive distribution agreement with Ultra Pain Products, Inc. ("UPPI") for the distribution of the Company's PainShield for another five years. Brian Murphy, CEO of NanoVibronix, commented, "We are thrilled to extend our partnership with Ultra Pain Products for another five years and secure a minimum purchase commitment of our products valued at $12 milli
NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today provided an update on recent business developments. Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., commented, "We have made substantial progress over the last several months with regards to expanding distribution, raising commercial awareness and pursuing reimbursements from regulatory authorities. Our products continue to deliver impressive results with high patient satisfaction and importantly, we believe are positioned to fill a void in the market. We are highly opti
Signs Term Sheet for a License and Supply Agreement for Distribution of UroShield NanoVibronix, Inc., (NASDAQ:NAOV) (the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave ("SAW") Portable Ultrasonic Therapeutic Devices, today announced it has signed a non-binding term sheet for a license and supply agreement with APOGEPHA Arzneimittel GmbH ("APOGEPHA"), a German pharmaceutical company, which specializes in the development, marketing, sales and distribution of urology products and services. Pursuant to the term sheet, the Company and APOHEPHA intend to enter into a definitive agreement, pursuant to which, APOHEPHA will dist